Delisting riskPopularity #4,220
Mereo BioPharma Group (ADR) (MREO)
Advances acquired rare-disease drug candidates through clinical development and partnerships.
$0.3489
vs last close+0.03 (+10.31%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 35.45% | 56.61M ADS | |
|---|---|---|---|
| 63 holders · as of Jun 30, 2026 | |||
| Strategic holders | 1.18% | 1.88M ADS | |
| 1 holder · as of Feb 11, 2022 | |||
| Other | 63.37% | 101.20M ADS | |
| remainder | |||
159.69M ADS (1 ADS = 5 ordinary shares) as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
63 holders · 56.61M shares · 13 new positions · 25 increased · 14 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Rubric Capital Management LP | 15.31M | 9.59% | 0 | Aug 14, 2026 |
| 683 Capital Management, LLC | 11.78M | 7.38% | −222.1K | Aug 14, 2026 |
| Bank of America Corp /DE/ | 8.20M | 5.13% | −6 | Aug 14, 2026 |
| Defilade Capital Management, L.P. | 7.56M | 4.73% | 0 | Aug 14, 2026 |
| Newtyn Management, LLC | 3.00M | 1.88% | −4.08M | Aug 14, 2026 |
| Tejara Capital Ltd | 2.04M | 1.28% | 0 | Aug 11, 2026 |
| UBS Group AG | 1.45M | 0.91% | −42.5K | Aug 13, 2026 |
| Two Sigma Investments, LP | 1.32M | 0.83% | +1.13M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 8.40% | 66.84M | 13G | May 15, 2026 |
| 683 Capital Management, LLC | 8.18% | 65.08M | 13G | Jan 6, 2026 |
| Bank of America Corp /DE/ | 5.10% | 40.98M | 13G | May 14, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.